BG Medicine's Q3 Revenues Shoot up 83 Percent, Plans FDA Submissions | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine today reported an 83 percent jump year over year in third-quarter revenues and progress in its plans to file for regulatory approval of its tests.

The Waltham, Mass.-based company posted $179,000 in revenues for the three months ended Sept. 30, up from $98,000 a year ago, which it attributed to an increase in sales of its galectin-3 test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.